Kidney Cancer: An Overview of Current Therapeutic Approaches.
The management of metastatic renal cell carcinoma (RCC) has evolved rapidly in recent years with several immunotherapy based combinations of strategies approved as first line therapies. Targeted strategies, including systemic antiangiogenesis agents and immune checkpoint blockade, form the basis of a therapeutic approach. With rising rates of recurrence after first line treatment, it is increasingly important to not only adopt a personalized treatment plan with minimal adverse events but also develop predictive biomarkers for response. This review discusses currently available first line and second line therapies in RCC and their pivotal data, with specific focus on ongoing clinical trials in the adjuvant setting, including those involving novel agents.
The Urologic clinics of North America